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Despite most new cancer treatments having relatively high costs and low health benefits, they are often funded ahead
of treatments for other illnesses. And yet, according to the article by Dan Greenberg and colleagues, most Israeli
oncologists and family physicians think that new cancer treatments should not receive such a high priority and that
cost-effectiveness data should be used to support funding decisions. In this commentary, I point out that the increasing
pressure worldwide when prioritizing health technologies to widen the scope of the benefits that are recognized
beyond just narrowly-defined health benefits would almost certainly include the special characteristics of cancer. Future
research would be worthwhile into how the criteria for prioritizing technologies should be incorporated into
prioritization frameworks in practice, including, in particular, how to resolve the inherent trade-offs.
This is a commentary on http://www.ijhpr.org/content/2/2/44/Commentary
The article by Dan Greenberg and colleagues reports on
a national survey of Israeli oncologists and family physi-
cians into their views on patient access and coverage de-
cisions with respect to interventions for cancer and
congestive heart failure (CHF) respectively [1]. Among
other things, the survey probed whether these two
groups of physicians regard cancer treatments as being
of higher value, and so of higher priority, than treat-
ments for other medical conditions – the latter, in effect,
represented by CHF (like cancer, a life-threatening con-
dition). Such a ‘cancer premium’ has been found in simi-
lar surveys in the US and Canada, and has been inferred
from the recommendations of organizations responsible
for prioritizing health technologies in several countries,
including Israel’s Public National Advisory Committee
(also known as ‘the Basket Committee’).
Why might cancer treatments be accorded special sta-
tus relative to other treatments? Given that cancer is
often fatal, many cancer interventions are, in effect, ‘end-
of-life’ treatments; and, correspondingly, cancer sufferers
are often also in greater need than other patients (albeit
cancer patients’ potential health gains from treatment
are almost always inevitably less). There are also un-
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stated.too arising from cancer’s fearsome reputation and asso-
ciated taboos [2].
Interestingly, the survey reported on in the article re-
veals that Israeli oncologists and family physicians, on
the whole, do not favor interventions for cancer over
ones for other illnesses. Most respondents think that
cancer (and also CHF) treatments should not receive a
higher priority, all else being equal. As well as being at
variance with the above-mentioned international evi-
dence, this finding challenges the Basket Committee’s
apparent favoritism, according to the authors, towards
cancer treatments.
The controversy internationally surrounding the fund-
ing of new cancer treatments (see the references in the
original article) derives from the stylized fact that most
new cancer treatments have very high costs and low
health benefits relative to treatments for other disease
groups. Some cost tens of thousands of dollars per pa-
tient (sometimes in excess of $US100,000, such as for
the drugs Vandetanib and Vismodegib mentioned in the
article) but delay death by only months (even weeks).
And yet many high cost cancer treatments do get funded
in Israel and other countries.
In light of the above-mentioned controversy, I find it
reassuring that a large majority (76%) of the surveyed
physicians think that cost-effectiveness data should be
used to support decisions about whether to include cancer
and CHF treatments – and, presumably, other technologiesThis is an Open Access article distributed under the terms of the Creative
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http://www.ijhpr.org/content/2/1/45too – in Israel’s health basket. It is worthwhile emphasiz-
ing that this finding is in the context of, according to the
authors, the Basket Committee not explicitly using the re-
sults from cost-effectiveness analysis (CEA), although
“studies have suggested that in many cases the recom-
mended technologies … are those with favorable cost-
effectiveness results”.
As a ‘health’ economist, in particular one from New
Zealand, it intrigues me that there continue to be deve-
loped countries, including Israel (and the US [3]), in which
formal CEA is not explicitly an important input into
health technology prioritization. In New Zealand – and
many other countries too [4] – CEA, specifically cost-
utility analysis, is a major component (but not the only
one) of the decision-making process followed by the
Pharmaceutical Management Agency (PHARMAC) [5].
The defining characteristic of such economics-based
frameworks – in contrast to non-economics-based
frameworks (e.g. ‘needs assessment’) – is that the out-
comes of alternative funding allocations are compared
relative to each other, with the objective of maximizing
the value of the various benefits realized from the money
spent. It seems that most respondents to the survey, as
well as the Basket Committee, subscribe to this over-
arching ‘philosophy’ – one which is probably common
sense to most people, being qualitatively similar to how
a household might think about allocating its budget
when doing the weekly grocery shopping, for example.
Where the possible confusion and debate arises, how-
ever, is with respect to how the various benefits realizable
from the competing health technologies are defined and
explicitly recognized. There is increasing pressure world-
wide to widen their scope beyond just narrowly-defined
health benefits such as are commonly represented using
Quality-Adjusted Life Years [6]. In the present context,
these wider benefits would almost certainly include the
special characteristics of cancer mentioned earlier (and
perhaps others). The challenge in general is how to in-
corporate these wider benefits into health technology
prioritization frameworks in practice, in a systematic and
transparent fashion that can also be easily communicated
to stakeholders, including the general public [7].
Strangely, despite the above-mentioned ringing en-
dorsement from Israeli physicians of the use of cost-
effectiveness data to support funding decisions, 65% of
oncologists and 55% of family physicians also agreed
(some strongly) with this statement in the survey: “Every
patient in Israel should have access to effective cancer
treatments regardless of their cost”. (For CHF the corre-
sponding percentages were 73% and 59%.) Really? Do
these respondents truly believe that every patient should
be treated regardless of the cost?
In my opinion, this seemingly aberrant result illustrates
the weakness of survey-based methodologies that restrictrespondents to categorical answers (on a five-point Likert
scale). I imagine that most people would prefer to answer
the question above, “it all depends”: on what is meant by
“effective cancer treatments” (how effective?) and also on
how costly such treatments might be (e.g. would $1 billion
per patient be too much?). Clearly, such caveats are rele-
vant, but for practical reasons were not included in the
questionnaire (in contrast to more open-ended questions).
Hence some of the survey results cannot be interpreted
literally (which the authors do not).
One result that perhaps can be taken at face value is
that over 90% of respondents think that judgments con-
cerning treatments’ value for money – fundamental to
health technology prioritization – should be made by a
third party other than the patient, physician or health in-
surance company. Interestingly, more physicians would
prefer such decisions to be made by an independent aca-
demic or research institution rather than by Israel’s Bas-
ket Committee or the Ministries of Health or Finance.
Does this preference suggest that physicians have lost
faith in the Basket Committee – supported by these
Ministries – due to its decisions in the past? The authors
do not speculate on this possibility. These results are
similar to a 2003 survey of physicians in which more
than two-thirds preferred that treatment-access deci-
sions be made by a committee of experts, but also in
contrast with several surveys in the early 2000s that
found that most physicians and the general public
trusted the system for updating the Health Basket, albeit
most were ignorant of the Basket Committee’s role [8].
It is a fact of life that whoever has to make prioritization
decisions will come in for some degree of opprobrium.
Saying no – sometimes with fatal consequences – is sel-
dom popular. Were some other body to replace the Basket
Committee, it too would inevitably be criticized by some
physicians and researchers. (Note, though, I am not im-
plying that the Basket Committee’s decisions are all be-
yond reproach.) Whoever is responsible for such
decisions faces an inherently difficult task. As men-
tioned in the article, because Israel is an early adopter of
technologies, prioritization decisions often have to be
based on incomplete information about the technolo-
gies’ effectiveness and cost-effectiveness. These infor-
mational deficiencies are magnified by another unusual
feature of Israel’s prioritization process (compared to
other countries): the sheer volume of technologies
assessed each year, usually numbering in the hundreds.
One of the authors’ conclusions is a recommendation
that the Israeli general public should also be surveyed
about the relative importance of cancer treatments vis-à-
vis other interventions – in essence, whether citizens, in
their dual roles as potential patients and health-insurance
taxpayers, share the preferences of oncologists and family
physicians. Similar comparisons of the attitudes of medical
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http://www.ijhpr.org/content/2/1/45professionals vis-à-vis the general public with respect to
access to new fertility technology have been performed
[9], and the public’s priorities over a wide range of tech-
nologies have been surveyed several times [8,10,11]. These
surveys, like the one reported on in the article, indicate
that the Israeli public probably gives less priority to cancer
treatments of relatively low cost-effectiveness than the
Basket Committee does. It would be interesting to know
whether the Committee is simply unaware of such fin-
dings or that its priorities are not affected by such infor-
mation (perhaps quite correctly).
In my opinion, it would be worthwhile broadening the
focus of such population-based research. Previous research
has confirmed that the Israeli general public considers the
usual kinds of criteria for prioritizing technologies associ-
ated with economics-based frameworks (as discussed
above) to be acceptable [10]. Likewise, in my own country,
PHARMAC recently completed a nationwide consultation
exercise to discover New Zealanders’ views on the appro-
priate criteria, with the results due out in 2014 [12]. But
the issue remains in both countries (and others): How
should these criteria be incorporated into prioritization
frameworks in practice, including, in particular, how to re-
solve the inherent trade-offs?
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